Gritstone Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 231
- Market Cap
- $57.5M
- Website
- http://www.gritstonebio.com
- Introduction
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
- Conditions
- Colonic NeoplasmsColorectal Neoplasms
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT05456165
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸NYU Langone Health, New York, New York, United States
🇺🇸Christ Hospital Cancer Center, Cincinnati, Ohio, United States
Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- Drug: GRT-R912, samRNA-Spikebeta-TCE11Drug: GRT-R914, samRNA-Spikebeta-TCE9Drug: GRT-R918, samRNA-SpikeOmicron-N-TCE11
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 342
- Registration Number
- NCT05435027
- Locations
- 🇿🇦
Newtown Clinical Research Centre, Johannesburg, South Africa
🇿🇦WITS RHI Shandukani Research Centre, Johannesburg, South Africa
🇿🇦Wits Vaccines & Infections Diseases Analytics (VIDA) Research Unit, Johannesburg, South Africa
A Screening Study Targeting Tumor-specific Antigens
- Conditions
- Metastatic Colorectal CancerStage II/III Colon Cancer
- Interventions
- Procedure: blood collection for research (next generation sequencing [NGS])Procedure: blood collection for research (HLA typing)Procedure: blood collection for research (circulating tumor DNA [ctDNA])
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05158621
- Locations
- 🇺🇸
Miami Cancer Institute, Miami, Florida, United States
🇺🇸Advanced Research, Tamarac, Florida, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05148962
- Locations
- 🇬🇧
University Hospitals Birmingham NHS, Birmingham, United Kingdom
🇬🇧University Hospital of Leicester NHS Trust, Leicester, United Kingdom
🇬🇧Manchester University, Manchester, United Kingdom
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Seattle Project Corporation
- Target Recruit Count
- 700
- Registration Number
- NCT05141721
- Locations
- 🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸Highlands Oncology, Springdale, Arkansas, United States
🇺🇸U.S.C Norris Cancer Center, Keck School of Medicine, Division of Medical Oncology, Los Angeles, California, United States
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
- Conditions
- Colorectal CancerShared Neoantigen-Positive Solid TumorsPancreatic CancerSolid TumorNon-Small Cell Lung Cancer
- Interventions
- Biological: GRT-C903Biological: GRT-R904Biological: nivolumabBiological: ipilimumab
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03953235
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸UCLA Medical Center, Santa Monica, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
A Study of Personalized Neoantigen Cancer Vaccines
- Conditions
- Urothelial CarcinomaNon Small Cell Lung CancerPancreatic Ductal AdenocarcinomaColorectal CancerGastroesophageal Adenocarcinoma
- Interventions
- Procedure: Blood collection for research (next-generation sequencing [NGS])Procedure: Blood collection for research (HLA typing)
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT03794128
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of a Personalized Neoantigen Cancer Vaccine
- Conditions
- Gastroesophageal AdenocarcinomaNon Small Cell Lung CancerColorectal CancerUrothelial Carcinoma
- Interventions
- Biological: GRT-C901Biological: GRT-R902Biological: nivolumabBiological: ipilimumab
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT03639714
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States